Anti-tumor necrosis factor-alpha treatment reduces allergic responses in an allergic rhinitis mouse model

Mo, Ji‐Hun; Kang, Eun-Sun; Quan, Steven Jige; Rhee, Chae‐Seo; Lee, C. H.; Kim, Dong Young

doi:10.1111/j.1398-9995.2010.02476.x

Cited by 69 publications

(57 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study, TNF-a levels of the serum and nasal samples in AR patients were significantly higher than in the control group. A possible explanation of high TNF-a could be that it is a principal mediator of the acute inflammatory response, including allergic rhinitis [24,25], and could be related to the lower levels of IL-10. A reduction of IL-10 with the increase of TNF-a could be attributed to the worsening of the allergy.…”

Section: Discussionmentioning

confidence: 99%

Immunological markers in allergic rhinitis patients treated with date palm immunotherapy

et al. 2012

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Immunological markers in allergic rhinitis patients treated with date palm immunotherapy

et al. 2012

View full text Add to dashboard Cite

show abstract

“…The influx of these inflammatory cells into nasal mucosa, in turn, results in production of leukotrienes and histamine, as well as proinflammatory cytokines, which is characterized by nasal hyposmia, hyperreactivity and blockage [25]. TNFα, an important proinflammatory cytokines produced by mast cells and eosinophils, is critical for the pathogenesis of AR [5, 26]. In previous studies, the level of TNFα has been found to be effectively inhibited by intranasal administration with steroids [27].…”

Section: Discussionmentioning

confidence: 99%

“…The inflammatory response is associated with increased number of eosinophils, and upregulated levels of proinflammatory cytokines, such as TNF-α, IL-4, IL-5 and IFN-γ [5-7]. The interaction between these cytokines and glandular structures results in a variety of symptoms, including rhinorrhea, nasal obstruction, post nasal drainage, sneezing, and nasal irritation [8].…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-133b Ameliorates Allergic Inflammation and Symptom in Murine Model of Allergic Rhinitis by Targeting Nlrp3

Xiao¹,

Jiang²,

Hu³

et al. 2017

Cell Physiol Biochem

View full text Add to dashboard Cite

Background: Emerging evidences indicate that post-transcriptional regulation by microRNAs is critical in allergic rhinitis (AR) pathogenesis. MircroRNA-133b (miR-133b) was recently suggested as a potential predictor of AR. However, the in vivo effect of miR-133b on AR is unclear. Methods: AR model was established in BALB/c mice by intraperitoneal sensitization and intranasal challenge with ovalbumin (OVA). MiR-133b agomir was then intranasally administrated to mice after OVA challenge for another 7 days. The symptom of nasal rubbing and sneezing were recorded after the last OVA challenge. Nasal mucosa tissues and serum were collected. MiR-133b expression, serum OVA-specific immunoglobulin E (IgE) concentration, proinflammatory cytokines (TNF-α, IL-4, IL-5, IL-10 and IFN-γ) levels, and Nlrp3 inflammasome activation were measured by RT-PCR, ELISA, western blotting or immunohistochemistry, respectively. Histopathologic changes were evaluated using hematoxylin and eosin and Sirius red staining. The luciferase activity and protein expression of Nlrp3 were also determined. Results: MiR-133b expression was significantly decreased in nasal mucosa of AR mice, which was restored by nasal administration with miR-133b agomir. Upregulation of miR-133b markedly reduced the concentration of OVA-specific IgE, the frequencies of nasal rubbing and sneezing, and the levels of cytokines (TNF-α, IL-4, IL-5 and IFN-γ). Levels of IL-4, IL-5, IL-10 and IFN-γ produced by cervical lymph node cells were significantly lowered in miR-133b agomir-treated mice. Moreover, miR-133b also appeared to strongly attenuate pathological alterations and eosinophils and mast cells infiltration in nasal mucosa. Notably, we demonstrated for the first time that miR-133b negatively regulated Nlrp3 expression through binding with the 3’ untranslated region of Nlrp3. Consequently, infection of miR-133b in nasal mucosa remarkably suppressed the Nlrp3 inflammasome activation, as evidenced by reduced Nlrp3, Caspase-1, ASC, IL-18 and IL-1 expressions. Conclusion: MiR-133b alleviates allergic symptom in AR mice by inhibition of Nlrp3 inflammasome-meditated inflammation. These findings provide us an insight into the potential role of miR-133b in relation to AR treatment.

show abstract

“…After consulting the relevant literature, we found the amount of OVA used in animal models generally ranges from 10 to 100 μg (Yamaki et al, 2005;Tumes et al, 2007;Liu et al, 2010;Oh et al, 2011), whereas the amount of Al(OH) 3 ranges from 1 and 5 mg. Moreover, there are several forms of Al(OH) 3 used in these experiments including powder, gel, solution, and other dosage forms (Yamaki et al, 2005;Zhao et al, 2005;Su et al, 2006;Tumes et al, 2007;Mo et al, 2011). Our study focused on these three dosage forms (powder, gel, and solution) in the production of an AR animal model.…”

Section: Discussionmentioning

confidence: 99%

Role of aluminum adjuvant in producing an allergic rhinitis animal model

Fan

Zhao

et al. 2014

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. This study evaluated different dosage forms of aluminum adjuvant in generating allergic rhinitis animal models. Forty female BALB/c mice were assigned to four groups, including three dosage forms of aluminum adjuvant [powder, gel, and hydrosolvent of aluminum hydroxide, Al(OH) 3 ] mixed with ovalbumin to simulate the symptoms of allergic rhinitis and one control group. Although the aluminum adjuvants were in different dosage forms, the content was 5 mg after conversion in all groups. The fourth group was given normal saline instead as a control. Mice of the powder group displayed typical symptoms of allergic rhinitis. We also found discrete eosinophils in the nasal mucosa of mice from the hydrosolvent group; however, no eosinophils were found in the gel group. These two groups both displayed cytotoxic symptoms and foreign body granuloma. Aluminum adjuvant used in producing animal models can induce foreign body granuloma and other untoward reactions, which are associated with the

show abstract

Anti-tumor necrosis factor-alpha treatment reduces allergic responses in an allergic rhinitis mouse model

Cited by 69 publications

References 18 publications

Immunological markers in allergic rhinitis patients treated with date palm immunotherapy

Immunological markers in allergic rhinitis patients treated with date palm immunotherapy

MicroRNA-133b Ameliorates Allergic Inflammation and Symptom in Murine Model of Allergic Rhinitis by Targeting Nlrp3

Role of aluminum adjuvant in producing an allergic rhinitis animal model

Contact Info

Product

Resources

About